Light adjustable lenses provide tailor-made refraction

Article

Pablo Artal discusses the use of light-adjustable lenses to increase the predictability of postop refractive outcomes.

Key Points

It is the combination of residual defocus and astigmatism that accounts for retinal image degradation and reduced quality of vision following IOL implantation in the majority of patients. Naturally, residual refractive errors can be corrected with spectacles, contact lenses or laser refractive surgery; it would, however, be preferable and more elegant to offer an advanced approach to cataract surgery that produces near perfect refraction in a single procedure.

Light adjustable IOLs: a quick introduction

The lenses have four main components: a silicone matrix polymer, a photoreactive macromer, a photoinitiator, and a UV absorbent layer at the back of the lens. Irradiation of the lens through a defined spatial profile polymerizes the macromer in the exposed region: the subsequent diffusion of un-reacted macromer to re-establish equilibrium throughout the lens produces a change in the shape of the lens and therefore a modification of the IOL power. For example, if the lens power needs to be increased, the central part is irradiated to cause the macromer in that area to polymerize. Then time is allowed for free macromer to diffuse down the resulting concentration gradient. The central zone bulges, the radius of curvature decreases, and the focal length decreases. Irradiating on the periphery causes macromer to leave the central zone, producing a flattening of the lens and increasing its focal length. Once the desired refraction (shape) is reached, the entire lens may be irradiated to polymerize all the macromer, making the state of the lens permanent. After this, the LAL may be exposed to UV light (for example, sunlight) and will remain unaltered.

Once the desired refraction is achieved, two additional photo-locking treatments need to be performed, to insure that the LAL is fixed and remains stable. From this point, the LAL behaves entirely as a conventional IOL. The irradiation of the LAL is performed using a custom digital light delivery device that is easy for trained ophthalmologists to operate, and the procedure is quick and comfortable for patients.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.